Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2022

Open Access 01-12-2022 | Tremor | Research

A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)

Authors: Cecilia Livermore, Hannah White, Loren Bailey, Ian Osborne, Ebenezer Oloyede, Olubanke Dzahini, Eromona Whiskey

Published in: BMC Psychiatry | Issue 1/2022

Login to get access

Abstract

Objective

The objective of the study is to explore the long-term effectiveness and tolerability of metoclopramide in the treatment of CIH.

Method

This study is a retrospective, observational cohort study of patients prescribed metoclopramide for CIH at the South London & Maudsley (SLaM) NHS Foundation Trust.

Results

Of the 96 patients identified, 14 patients were eligible for inclusion in our study. Five patients continued treatment with a mean duration of 27 months (SD = 17.8), and one patient continued until transfer with a duration of 3 months. Eight patients discontinued treatment after a mean duration of 8 months.

Conclusion

Metoclopramide may be an effective and tolerated drug in CIH, but more data is required to establish its place in the pharmacotherapy of this condition.
Literature
1.
2.
Henzi I, Walder B, Tramer MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth. 1999;83(5):761–71.CrossRefPubMed
3.
Martindale (2021). Digital Medicines Information Suite - metoclopramide. [online] MedicinesComplete. Available at: https://​www.​medicinescomplet​e.​com/​#/content/martindale/11464-n#content%2Fmartindale%2F11464-n%2311464-n [Accessed 19 May 2021].
4.
Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, Lerner PP, Bergman J, Lerner V. Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine. J Clin Psychopharmacol. 2016;36(3):200–5.CrossRefPubMed
5.
6.
Legge SE, Hamshere M, Hayes RD, Downs J, O’Donovan MC, Owen MJ, MacCabe JH. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174(1–3):113–9.CrossRefPubMedPubMedCentral
7.
Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology. 2006;185(3):265–73.CrossRefPubMed
8.
9.
10.
Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33(3):225–38.CrossRefPubMed
11.
12.
Rao AS, Camilleri M. metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–9.CrossRefPubMed
13.
14.
Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: A pilot study. Biol Psychiat. 1996;40(11):1132–4.CrossRefPubMed
15.
Van der Poorten T, et al. The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: a systematic review. Clin Case Rep. 2019;7:2108–13.CrossRefPubMedPubMedCentral
16.
McKane JP, et al. Hyoscine patches in clozapine-induced hypersalivation. Psychiatr Bull. 2001;25:277.CrossRef
17.
18.
Duggal HS. Glycopyrrolate for clozapine-induced sialorrhea. Prog Neuropsychopharmacol Boil Psychiatry. 2007;31:1546–7.CrossRef
19.
Sockalingam S, et al. Review: Insufficient evidence to guide use of drugs for clozapine induced hypersalivation. Evid Based Ment Health. 2009;12:12.CrossRefPubMed
20.
Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21(2):99–103.CrossRefPubMed
21.
22.
Gupta S, Khastgir U, Croft M, Roshny S. Management of clozapine-induced sialorrhoea. BJPsych. Advances. 2019;26(2):106–8.
Metadata
Title
A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)
Authors
Cecilia Livermore
Hannah White
Loren Bailey
Ian Osborne
Ebenezer Oloyede
Olubanke Dzahini
Eromona Whiskey
Publication date
01-12-2022
Publisher
BioMed Central
Keywords
Tremor
Clozapine
Published in
BMC Psychiatry / Issue 1/2022
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-022-03940-0

Other articles of this Issue 1/2022

BMC Psychiatry 1/2022 Go to the issue

Research

Anxiety and its associated factors among inmates in ARBA Minch and JINKA town, southern Ethiopia

Research article

Acting with awareness moderates the association between lifetime exposure to interpersonal traumatic events and craving via trauma symptoms: a moderated indirect effects model

Study protocol

Neuroimmunological investigations of cerebrospinal fluid in patients with recent onset depression – a study protocol

Research

Effectiveness of crisis resolution home treatment for the management of acute psychiatric crises in Southern Switzerland: a natural experiment based on geography

Research

Resident and staff perceptions of an activity- and recovery-based intervention in supported housing for people with severe mental illness – a longitudinal pilot study

Research

Adolescent anxiety and depression: burden of disease study in 53,894 secondary school pupils in the Netherlands